{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:22:19Z","timestamp":1792650139749,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":2655,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/annonc\/mds257","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T15:14:01Z","timestamp":1345648441000},"page":"viii10-viii14","source":"Crossref","is-referenced-by-count":104,"special_numbering":"S8","title":["Melanoma as a model tumour for immuno-oncology"],"prefix":"10.1016","volume":"23","author":[{"given":"M.","family":"Maio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds257_bb0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds257_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mds257_bb0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds257_bb0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejca.2009.10.032","article-title":"Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline","volume":"46","author":"Garbe","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds257_bb0030","unstructured":"PROLEUKIN\u00ae (aldesleukin) prescribing information http:\/\/www.proleukin.com\/health-care-professional\/tools\/pi.jsp (October 2011, date last accessed)"},{"key":"10.1093\/annonc\/mds257_bb0035","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds257_bb0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds257_bb0045","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds257_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0952-7915(00)00195-3","article-title":"Immunity against cancer: lessons learned from melanoma","volume":"13","author":"Houghton","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1093\/annonc\/mds257_bb0055","first-page":"139","article-title":"Melanoma: is immunotherapy of benefit?","volume":"37","author":"Faries","year":"2003","journal-title":"Adv Surg"},{"key":"10.1093\/annonc\/mds257_bb0060","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.183.3.725","article-title":"Human tumor antigens recognized by T lymphocytes","volume":"183","author":"Boon","year":"1996","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mds257_bb0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<323::AID-JCP2>3.0.CO;2-#","article-title":"T-cell recognition of melanoma-associated antigens","volume":"182","author":"Castelli","year":"2000","journal-title":"J Cell Physiol"},{"key":"10.1093\/annonc\/mds257_bb0070","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","article-title":"A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer","volume":"66","author":"Epping","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds257_bb0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1093\/annonc\/mds257_bb0080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF02786397","article-title":"Human tumor antigens recognized by T-cells","volume":"16","author":"Kawakami","year":"1997","journal-title":"Immunol Res"},{"key":"10.1093\/annonc\/mds257_bb0085","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1084\/jem.188.6.1005","article-title":"Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage","volume":"188","author":"Lupetti","year":"1998","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mds257_bb0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CMR.0b013e32832eabd5","article-title":"Spontaneous regression of metastases from melanoma: review of the literature","volume":"19","author":"Kalialis","year":"2009","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mds257_bb0095","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/jnci\/93.14.1047","article-title":"Spontaneous regression of melanoma may offer insight into cancer immunology","volume":"93","author":"Printz","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds257_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1309\/4EJ9KL7CGDENVVLE","article-title":"Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions","volume":"124","author":"Wenzel","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1093\/annonc\/mds257_bb0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2007.06.009","article-title":"Tumor immunoediting and immunosculpting pathways to cancer progression","volume":"17","author":"Reiman","year":"2007","journal-title":"Semin Cancer Biol"},{"key":"10.1093\/annonc\/mds257_bb0110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1755-148X.2010.00799.x","article-title":"Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy","volume":"24","author":"Speeckaert","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1093\/annonc\/mds257_bb0115","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/labinvest.3780318","article-title":"Autoimmune melanocyte destruction in vitiligo","volume":"81","author":"van den Wijngaard","year":"2001","journal-title":"Lab Invest"},{"key":"10.1093\/annonc\/mds257_bb0120","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1046\/j.0022-202x.2001.01605.x","article-title":"Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo","volume":"117","author":"Le Gal","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1093\/annonc\/mds257_bb0125","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2001.19.15.3477","article-title":"Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma","volume":"19","author":"Phan","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds257_bb0130","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1093\/annonc\/mds257_bb0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1188\/09.CJON.81-89","article-title":"Management of metastatic melanoma: nursing challenges today and tomorrow","volume":"13","author":"Rubin","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"10.1093\/annonc\/mds257_bb0140","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds257_bb0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","article-title":"Adoptive cell therapy for the treatment of patients with metastatic melanoma","volume":"21","author":"Rosenberg","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1093\/annonc\/mds257_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mds257_bb0155","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds257_bb0160","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","article-title":"Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion","volume":"56","author":"Blank","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/mds257_bb0165","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity associated with immunotherapy of cancer","volume":"118","author":"Amos","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds257_bb0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/157489208784638767","article-title":"Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: recent findings","volume":"3","author":"Lens","year":"2008","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1093\/annonc\/mds257_bb0175","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds257_bb0180","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1479-5876-9-78","article-title":"Methylation levels of the \u201clong interspersed nucleotide element-1\u201d repetitive sequences predict survival of melanoma patients","volume":"9","author":"Sigalotti","year":"2011","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mds257_bb0185","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrg2640","article-title":"The impact of retrotransposons on human genome evolution","volume":"10","author":"Cordaux","year":"2009","journal-title":"Nat Rev Genet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419376859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419376859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/suppl_8\/viii10\/6673893\/mds257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:15:07Z","timestamp":1582197307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419376859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":36,"alternative-id":["S0923753419376859"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds257","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}